NCT07229807进行中（未招募）3 期
A Phase 3 Study of ZSP1273 in Otherwise Healthy Children 2-11 Years Old With Influenza A
Guangdong Raynovent Biotech Co., Ltd1 个研究点 分布在 1 个国家目标入组 119 人开始时间: 2025年11月22日最近更新:
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 119
- 试验地点
- 1
- 主要终点
- Time to Alleviation of Symptoms
研究概览
简要总结
This trial is conducted in China. The aim of the trial is to investigate safety and efficacy of ZSP1273 granules
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 2 Years 至 11 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants and their guardians who are able to understand the study and comply with all study procedures, and willing to provide written informed consent/assent prior to the predose examinations appropriately.
- •Male or female participants aged ≥ 2 to ≤11 years at the time of signing the informed consent form.
- •Participants with a diagnosis of influenza virus infection confirmed by all of the following:
- •Positive rapid antigen test (RAT) for influenza with nasal or throat swabs;
- •The time interval between the onset of symptoms and enrollment is 48 hours or less;
- •Fever ≥ 38ºC (axillary temperature); and at least one following respiratory symptoms associated with influenza virus infection is present
排除标准
- •Participants with severe influenza virus infection；
- •Participants with any medical history in gastrointestinal that interferes with the absorption of drugs；
- •Immunodeficiency,including malignant tumor,organ or marrow transplant,human immunodeficiency virus [HIV] infection,or patients receiving immunosuppressant therapy 3 months prior to enrollment；
- •Have received any other investigational products within 3 months prior to dosing；
- •Positive urine pregnancy test；
- •Participants with concurrent infections requiring antimicrobial therapy；
- •Participants who are considered inappropriate for the study by the investigator.
研究组 & 干预措施
ZSP1273
Experimental
干预措施: ZSP1273 (Drug)
Oseltamivir
Active Comparator
干预措施: Oseltamivir (Drug)
结局指标
主要结局
Time to Alleviation of Symptoms
时间窗: DAY1~DAY15
Participants assessed the severity of influenza-associated symptoms
次要结局
- Plasma concentrations of ZSP1273(DAY1~5)
- Number of participants with treatment-related adverse events as assessed by CTCAE v5.0(DAY1~15)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DMType 2 DiabetesNCT06199505Gan and Lee Pharmaceuticals, USA153
已完成
3 期
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension StudyMalignant MelanomaNCT04889118Merck Sharp & Dohme LLC131
尚未招募
1 期
JSKN033 in Chinese Subjects with Advanced Malignant TumorsAdvanced Malignant TumorsNCT06770881Jiangsu Alphamab Biopharmaceuticals Co., Ltd430
进行中（未招募）
1 期
Safety, Tolerability, Pharmacokinetics and Immunogenicity Study of GB002 Recombinant Peptide Inhalation Solution in Healthy SubjectsHealthyNCT06423261Zhejiang Echon Biopharm Limited100
进行中（未招募）
3 期
A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast CancerAdvanced Breast CancerNCT05257395Xuanzhu Biopharmaceutical Co., Ltd.397